MAPT and Alzheimer disease: In fact, CSF and plasma p-tau217 have already shown equivalent performance in the identification of AD pathology [13, 21], while p-tau181 and p-tau231 measured in CSF had a higher AUC in identifying amyloid and tau in PET, in comparison to plasma measurements [38, 39].